<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140004125A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140004125</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13739707</doc-number><date>20130111</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>24</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>244</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>4241581</main-classification><further-classification>5303892</further-classification><further-classification>536 2353</further-classification><further-classification>4353201</further-classification><further-classification>43525233</further-classification><further-classification>514 44  R</further-classification><further-classification>4352542</further-classification><further-classification>435335</further-classification></classification-national><invention-title id="d0e43">IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>13109680</doc-number><date>20110517</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8377442</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13739707</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>12464381</doc-number><date>20090512</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>7943121</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13109680</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>11472813</doc-number><date>20060621</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>7531166</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>12464381</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>60692830</doc-number><date>20050621</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Xoma Technology Ltd.</last-name><address><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Masat</last-name><first-name>Linda</first-name><address><city>Walnut Creek</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Haak-Frendscho</last-name><first-name>Mary</first-name><address><city>Newark</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Horwitz</last-name><first-name>Arnold H.</first-name><address><city>San Leandro</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Chen</last-name><first-name>Gang</first-name><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Roell</last-name><first-name>Marina</first-name><address><city>Concord</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>XOMA TECHNOLOGY LTD.</orgname><role>02</role><address><city>Berkeley</city><state>CA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">An IL-1&#x3b2; binding antibody or IL-1&#x3b2; binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1&#x3b2; binding polypeptide. IL-1&#x3b2; binding antibodies or IL-1&#x3b2; binding fragments thereof are provided which have desirable affinity and potency.</p></abstract></us-patent-application>